Plain-English translation of NCT04724018 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether two medications called Sacituzumab Govitecan and Enfortumab Vedotin work better together to treat advanced bladder cancer that has spread to other parts of the body or stopped responding to previous treatments. One of these medications is already approved for bladder cancer, while the other has shown promise but isn't yet approved for this type of cancer. The study is also testing whether adding a third medication called —which helps your immune system fight cancer—could make the combination even more effective.
Many people with advanced bladder cancer stop responding to standard chemotherapy and immunotherapy treatments, leaving them with limited options. Researchers believe that combining these two medications, which work in different ways to attack cancer cells, might help control the cancer better than each drug alone or existing treatments.
You likely qualify if…
You likely don't qualify if…
You will receive the study medications as injections on days 1 and 8 of each 21-day cycle. The first phase of the trial determines the safest and most effective dose by starting with lower doses and gradually increasing them if tolerated well. Once the best dose is found, the second phase expands to more patients to confirm how well the medication combination works. You will need to visit the clinic regularly for treatment, blood work, and scans to check how your cancer is responding, and the trial will continue until your cancer progresses or you experience unacceptable side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States